Varian Medical (NYSE:VAR) yesterday topped the consensus earnings forecast on Wall Street with its fiscal first-quarter results, despite a slide into red ink, sending share prices up today in pre-market trading. The Palo Alto, Calif.-based company posted losses of -$112.2 million, or -$1.22 per share, on sales of $678.5 million for the three months ended Dec. […]
MassDevice Earnings Roundup
Accuray shares rise on FY2018 Q2 EPS beat
Shares in Accuray (NSDQ:ARAY) have risen today after the medical device maker beat expectations on Wall Street with its 2nd quarter earnings results. The Sunnyvale, Calif.-based company posted losses of $4.7 million, or 6¢ per share, on sales of $100.3 million, seeing losses shrink 49.6% while sales grew 14.7% compared with the same period during the […]
Global sales for Abbott’s diabetes biz jumps 33% in Q4
Worldwide sales for Abbott‘s (NYSE:ABT) diabetes business jumped 33% in the fourth quarter of 2017, the company reported, driven largely by its FreeStyle Libre continuous glucose monitoring system. The device is the only CGM system on the market that is calibrated at the factory and eliminates the need for people with diabetes to perform routine fingersticks. Get the […]
Corindus partners with Medtronic on interventional cardiology courses, releases prelim Q4, 2017 earnings
Corindus Vascular Robotics (OTC:CVRS) yesterday said it will co-sponsor training courses with medical giant Medtronic (NYSE:MDT) on transradial access techniques and robot-assisted vascular interventions, and released preliminary earnings results for its fourth quarter and fiscal year 2017. The Waltham, Mass.-based company said it plans to help sponsor courses designed to train for operations using robotic-assisted percutaneous coronary interventions using […]
Pharma revenue drives Johnson & Johnson’s Q4 beat
Shares in Johnson & Johnson (NYSE:JNJ) fell yesterday after the healthcare giant topped Wall Street’s expectations for fourth-quarter results but missed analysts’ forecast for the full-year. Despite taking a $13.6 billion hit to its unremitted foreign earnings thanks to new efforts to reform the U.S. tax system, the company said it is pleased with the legislation and that it […]
GE Healthcare’s Q4 numbers rise despite parent’s slide to red ink
General Electric (NYSE:GE) saw its fourth-quarter and annual numbers slide, but its GE Healthcare division managed to increase its sales and profits for both periods. GE Healthcare’s Q4 profits rose 12.5% to $1.16 billion on sales growth of 5.9% to $5.40 billion; full year profits were up 9.1% to $3.45 billion on sales growth of 4.5% […]
Abbott shares up on Q4, 2017 earnings beat
Shares in Abbott (NYSE:ABT) have risen today in pre-market trading after the medical device maker beat expectations on Wall Street with its fourth quarter and full fiscal year 2017 earnings results. The Abbott Park, Ill.-based company posted losses of $828 million, or 50¢ per share, on sales of $7.6 billion for the 3 months ended December […]
ResMed tops Wall Street’s Q2 earnings forecast, despite $127m tax hit
The U.S. tax reform passed last year dealt a $127 million blow to ResMed (NYSE:RMD) during its fiscal second quarter, but the sleep apnea company still managed to top Wall Street’s consensus earnings forecast with its Q2 results. San Diego-based ResMed posted profits of $9.5 million, or 7¢ per share, on sales of $601.3 million for […]
Johnson & Johnson logs Q4 beat, misses with 2017 numbers
Update: Now includes detailed medical device segment results Johnson & Johnson (NYSE:JNJ) today beat Wall Street’s expectations with its fourth-quarter results but missed the consensus forecast for the full year. The New Brunswick, N.J.-based healthcare conglomerate swung to red ink during the quarter, posting losses of -$10.71 billion, or -$3.99 per share, on sales of […]
Allergan talks taxes and competition in 2018 outlook
Allergan (NYSE:AGN) had a busy, and occasionally fraught, 2017. After the company inked a controversial deal with a Native American tribe to shield its Restasis patents from review, a federal judge in Texas invalidated the IP, helping to clear the way for generics. And just last week, Allergan announced that it would slash 1,400 jobs in an effort to cut […]
Novocure revenues climb in Q4, FY17 prelims
Novocure (NSDQ:NVCR) shares rose slightly this morning after the cancer-treatment developer reported its preliminary fourth quarter and full-year revenues. The St. Helier, N.J.-based company said it expects to land $53.7 million in net revenue for the fourth quarter of 2017, up 77% from the same period last year. For the full year, Novocure anticipates it will […]